Indications And Dose
Peptic ulcer disease ▶BY MOUTH ▶Adult: 20 mg once daily for 4–8 weeks NSAID-associated gastric ulcer ▶BY MOUTH ▶Adult: 20 mg once daily for 4–8 weeks ▶BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION ▶Adult: 20 mg daily continue until oral administration possible, injection to be given over at least 3 minutes Prophylaxis of NSAID-associated gastric ulcer in patients with an increased risk of gastroduodenal complications who require continued NSAID treatment ▶BY MOUTH ▶Adult: 20 mg daily Prophylaxis of NSAID-associated gastric or duodenal ulcer ▶BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION ▶Adult: 20 mg daily continue until oral administration possible, injection to be given over at least 3 minutes Gastro-oesophageal reflux disease (in the presence of erosive reflux oesophagitis) ▶BY MOUTH ▶Child 1–11 years (body-weight 10–19 kg): 10 mg once daily for 8 weeks ▶Child 1–11 years (body-weight 20 kg and above): 10–20 mg once daily for 8 weeks ▶Child 12–17 years: Initially 40 mg once daily for 4 weeks, continued for further 4 weeks if not fully healed or symptoms persist; maintenance 20 mg daily ▶BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION ▶Adult: 40 mg daily continue until oral administration possible, injection to be given over at least 3 minutes Severe oesophagitis ▶BY MOUTH ▶Adult: 40 mg once daily for 8 weeks, continue as maintenance treatment if appropriate Severe oesophagitis, refractory to initial treatment ▶BY MOUTH ▶Adult: 40 mg twice daily Gastro-oesophageal reflux disease (in the absence of oesophagitis) ▶BY MOUTH ▶Child 1–11 years (body-weight 10 kg and above): 10 mg once daily for up to 8 weeks ▶Child 12–17 years: 20 mg once daily for up to 4 weeks ▶Adult: 20 mg once daily 4 or 8 weeks, then 20 mg daily if required ▶BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION ▶Adult: 20 mg once daily continue until oral administration is possible, injection to be given over at least 3 minutes Uninvestigated dyspepsia ▶BY MOUTH ▶Adult: 20 mg once daily for 4 weeks Zollinger–Ellison syndrome ▶BY MOUTH ▶Adult: Initially 40 mg twice daily, adjusted according to response; usual dose 80–160 mg daily, daily doses above 80 mg should be given in 2 divided doses Severe peptic ulcer bleeding (following endoscopic treatment) ▶INITIALLY BY INTRAVENOUS INFUSION Gastro-intestinal system ▶Adult: Initially 80 mg, to be given over 30 minutes, then (by continuous intravenous infusion) 8 mg/hour for 72 hours, then (by mouth) 40 mg once daily for 4 weeks Helicobacter pylori eradication [in combination with other drugs (see Helicobacter pylori infection p. 89)] ▶BY MOUTH ▶Adult: 20 mg twice daily for 7 days for first- and second-line eradication therapy; 10 days for third-line eradication therapy l UNLICENSED USE Tablets and capsules not licensed for use in children 1–11 years. ▶In adults g Combination regimens and durations for Helicobacter pylori eradication may differ from product literature but adhere to national guidelines. h See Helicobacter pylori infection p. 89 for further information. Esomeprazole may be used as detailed below, although these situations are considered outside the scope of its licence: . g treatment of peptic ulcer disease, h see Peptic ulcer disease p. 76 for further information; . g treatment of severe oesophagitis, refractory to initial treatment, h see Gastro-oesophageal reflux disease p. 88 for further information; . g treatment of uninvestigated dyspepsia, h see Dyspepsia p. 72 for further information. ▶With oral use in adults g Duration of treatment of gastro- oesophageal reflux disease (in the absence of oesophagitis) differs from product literature but adheres to national guidelines. h See Gastro-oesophageal reflux disease p. 88 for further information.
Source page 105